Schwingshackl, A., Kimura, D., Rovnaghi, C.R., et al. (2016) Regulation of Inflammatory Biomarkers by Intravenous Methylprednisolone in Pediatric ARDS Patients: Results from a Double-Blind, Placebo-Controlled Randomized Pilot Trial. Cytokine, 77, 63-71.
https://doi.org/10.1016/j.cyto.2015.10.007

has been cited by the following article:

• TITLE: Surfactant Protein D for Pathological Evaluation of Infant Acute Respiratory Distress Syndrome Caused by Respiratory Syncytial Virus Infection

  AUTHORS: Daisuke Tamura, Shun Inoue, Takatoshi Oishi, Ayafumi Ozaki, Takanori Yamagata

  KEYWORDS: Infants, Respiratory Syncytial Virus, Acute Respiratory Distress Syndrome, Surfactant Protein D, KL-6

  JOURNAL NAME: Open Journal of Pediatrics, Vol.10 No.4, December 4, 2020

  ABSTRACT: Pediatric respiratory syncytial viral infection (RS) usually shows relatively good outcome; however, when it accompanies acute respiratory distress syndrome (ARDS), this becomes fatal. We experienced three pediatric patients with RS + ARDS, with all showing good outcome with steroid pulse therapy. We wish to emphasize; 1) steroid pulse therapy may become an option for this condition, and 2) plasma KL-6 and surfactant protein D levels may become a biomarker reflecting the disease progression/condition. Patients were, aged 1 month, 1 year 5 months, and 1 year 11 months. In all three, the respiratory condition deteriorated rapidly, requiring invasive ventilator management. Although the effectiveness of steroid treatment for ARDS is controversial, very severe condition prompted us to employ steroid pulse therapy, after which, oxygenation rapidly improved without adverse events. Plasma KL-6 and surfactant protein D levels were measured during exacerbations of ARDS, steroid pulse therapy, and recovery. Surfactant protein D levels were closely associated with oxygenation, suggesting this substance level might be a biomarker of ARDS caused by the disruption of the alveolar epithelial lining and to understand oxygenation without time lag.